Professor Steve Conlan
Personal Chair
Medicine
Telephone: (01792) 295386
Room: Office CNH - 009
Ground Floor
Institute of Life Science 2
Singleton Campus

Steve Conlan is Professor of Molecular and Cell Biology at Swansea University Medical School. He is head of the Reproductive Biology and Gynaecological Oncology research group, and Director of Strategic Partnerships for the Medical School.

Prof Conlan is a Fellow of the Royal Society of Biology (FRSB), and a Trustee of the British Society of Nanomedicine. He is a Senior Affiliate Member of The Methodist Hospital Research Institute, Houston Texas, and Distinguished Professor at Xi'an Jiaotong University, Suzhou Academy, China.

Steve has achieved success in developing infrastructure bids, strategic national and international collaborations, and industrial partnerships.

He was a founding Director of the £22 Million Centre for NanoHealth  [CNH] at Swansea University, an interdisciplinary R&D facility bringing together clinicians, biologists, physicists, chemists, engineers and businesses together under one roof to deliver advances in nanomedicine.

Steve is now Strategic Director of the Celtic Advanced Life Science Innovation Network (CALIN), a €12Million Ireland-Wales INTERREG operation established to build a innovation bridge between Wales and Ireland in life sciences. CALIN partners include Swansea (lead), Bangor, Cardiff, University College Dublin, National University Galway, University College Cork.

He currently leads industry facing R&D projects with industrial partners including Axis Bioservices, Bruker nano, GSK, GE Healthcare, Ig Innovations (part of the Abbott group), Porvair, and ReNeuron.

Prof Conlan’s research focuses on the application of molecular, cellular and nano biology approaches to understanding gynaecological pathologies including cancer and infertility. He has a particular interest in the impact of aberrant transcription and epigenetic processes, and advanced therapeutics (Antibody Drug Conjugates, exosomes, and nanoparticle deliver systems). He is affiliated to the Wales Cancer Research Centre, a virtual network in Wales, where he coordinates activity in developing novel therapeutics for ovarian cancer with colleagues in Swansea and Cardiff.

As Director of Strategic Partnerships, and member of the University’s Internationalisation Strategy Group, he leads strategic collaborative initiatives with Grenoble - France, Houston - US and Suzhou and Wuhan – China.

Prof Conlan holds an honorary consultant position in the Abertawe Bro Morgannwg NHS Board, working with clinical colleagues in Singleton Hospital Swansea and The Princess of Wales Hospital Bridgend.

Areas of Expertise

  • Reproductive Biology and Gynaecological Oncology
  • Molecular and Cell Biology
  • Nanomedicine
  • Translational Biomedical Research

Publications

  1. & Measuring the impact on impedance spectroscopy of pseudo-reference electrode accumulations. Electrochemistry Communications 105, 106508
  2. et. al. On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology 14(7), 629-635.
  3. & Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11. Journal of Molecular Medicine
  4. & Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors. Biosensors and Bioelectronics 141, 111386
  5. & HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. Nanomedicine: Nanotechnology, Biology and Medicine 17, 254-265.

See more...

Teaching

  • PM-317 Genetics of Cancer

    This module will provide students with an advanced understanding about the genetic mechanisms involved in carcinogenesis, and how these underlying processes and molecules affect the human body.

  • PMND00 Nanomedicine Research Dissertation

    This module builds on the knowledge and skills developed in teaching components in part one of their relevant programme. Students will work independently in order to critically explore and add to the evidence base for a topic of relevance to their area of study within nanomedicine.

  • PMNM11 Nanomedicines, pharmaceuticals and advanced therapeutics

    This module will explore the history and development of molecular medicines and pharmaceuticals, providing the basis for an advanced understanding of next generation therapeutic approaches. Using landmark technology and chemical development phases informed by separation science and mass spectrometry, the module uses an application driven approach to provide the student with an extensive knowledgebase of drug development, the pharmaceutical industry and nanotherapeutics. Students will be able to characterize and map the path of a drug from administration, to metabolism and elimination, and critically evaluate drug design and delivery approaches. Traditional small chemical entities used in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. Common target oncology and non-oncology disorders will provide the context; with students encouraged to explore targeted nanoparticle fabrication, drug encapsulation and release profiling, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems. Future molecular medicines such as antibody drug conjugates and kinase inhibitors will be taught by guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.

Supervision

  • Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine (current)

    Student name:
    PhD
    Other supervisor: Dr Ricardo Del Sol Abascal
  • "Design and Evaluation of anti-STEAP2 antibodies to treat aggressive Prostate Cancer" (current)

    Student name:
    PhD
    Other supervisor: Prof Shareen Doak
  • Evaluation of a New Class of ADC Payloads (current)

    Student name:
    PhD
    Other supervisor: Prof Deyarina Gonzalez
  • Monitoring inflammatory response to pre-infectious pathogens. (current)

    Student name:
    MSc
    Other supervisor: Dr Ricardo Del Sol Abascal
  • Biosensors for enhanced in-vitro fertilisation (IVF) outcomes (current)

    Student name:
    PhD
    Other supervisor: Ms Sofia Rodrigues Teixeira
  • Graphene-based amylase biosensor for infection diagnosis (no change) (current)

    Student name:
    PhD
    Other supervisor: Dr Ernest Azzopardi
  • Therapeutic exosomes as novel treatment for ovarian cancer (current)

    Student name:
    PhD
    Other supervisor: Prof Deyarina Gonzalez
  • Targeting vulnerabilities of mTORC1 hyperactive cancer cells using clinically approved drugs that induce cell stress and selective cytotoxicity (current)

    Student name:
    PhD
    Other supervisor: Prof Deyarina Gonzalez
  • Geochemistry of cancer: Effect of Selenium as a treatment and characterization of a copper biomarker of ovarian cancer (current)

    Student name:
    PhD
    Other supervisor: Dr Lewis Francis
  • Targeted therapies for oncology applications (current)

    Student name:
    PhD
    Other supervisor: Prof Deyarina Gonzalez
  • Biomimetic tridimensional scaffold to investigate ovarian tumour response to therapy (current)

    Student name:
    PhD
    Other supervisor: Prof Deyarina Gonzalez
  • The Identification Biomarkers associated with the development of Ovarian Cancer in at Risk Patients With Ovarion Endometriosis (awarded 2019)

    Student name:
    MSc
    Other supervisor: Prof Deyarina Gonzalez
  • 'Aberrant Epigenetics and the Differentiation of Gynaecological Cancers' (awarded 2018)

    Student name:
    PhD
    Other supervisor: Dr Lewis Francis
  • 'Antibody-drug conjugates for gynaecological cancers.' (awarded 2018)

    Student name:
    PhD
    Other supervisor: Prof Deyarina Gonzalez
  • 'The impact of HBO1 in Ovarian Cancer' (awarded 2018)

    Student name:
    PhD
    Other supervisor: Dr Lewis Francis
  • 'The molecular mechanisms for chemo-preventative effects of aspirin on prostate cancer' (awarded 2017)

    Student name:
    MSc
    Other supervisor: Prof Shareen Doak
  • 'Role of chronic urinary infection in the pathophysiology of overactive bladder syndrome' (awarded 2017)

    Student name:
    MD
    Other supervisor: Prof Deyarina Gonzalez
  • 'A platform to determine mutation events in the cancer genome and chemical toxicity' (awarded 2017)

    Student name:
    PhD
    Other supervisor: Prof Paul Lewis
  • 'Investigations into novel diagnostic biomarkers for oesophageal adenocarcinoma' (awarded 2017)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins

Research Groups

  • Reproductive Biology and Gynaecological Oncology

    Reproductive biology and gynaecological oncology research in Swansea covers basic and translational research into: Uterine pathologies, Gynaecological and in vitro fertilisation

Key Grants and Projects

  • CALIN (Celtic Advanced Life Science Innovation Network) 2016

    Strategic Director